HOME   |    PDF   |   


Title

Advancement of next-generation sequencing in cancer research and clinical oncology

 

Authors

Nada Alshelali 1, Magdah Ganash1, Mona Alharbi1, Loubna Mira 2, Nadia Bagatian 2, Peter Natesan Pushparaj 2,*, Zeenat Mirza 3, 4,* & Sajjad Karim 2

 

Affiliation

1Department of Biological Sciences, Faculty of Science, King Abdulaziz University, Jeddah, Saudi Arabia; 2Institute of Genomic Medicine Sciences, King Abdulaziz University, Jeddah, Saudi Arabia; 3Eco Health Unit, King Fahd Medical Research Center, King Abdulaziz University, Jeddah, Saudi Arabia; 4Department of Medical Laboratory Sciences, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah, Saudi Arabia; *Corresponding author

 

Email

Nada Alshelali - E-mail: nalshelali0003@stu.kau.edu.sa
Magdah Ganash - E-mail: mganash@kau.edu.sa
Mona Alharbi - E-mail: mgalharbi@kau.edu.sa
Loubna Mira - E-mail: lobnamira@hotmail.com
Nadia Bagatian - E-mail: nbaktian@kau.edu.sa
Peter Natesan Pushparaj - E-mail: pnatesan@kau.edu.sa
Zeenat Mirza - E-mail: zmirza1@kau.edu.sa
Sajjad Karim - E-mail: skarim1@kau.edu.sa
 

Article Type

Review

 

Date

Received October 1, 2026; Revised October 31, 2026; Accepted October 31, 2026, Published October 31, 2026

 

Abstract

Cancer is a genomic disease driven by somatic and germline alterations, including single-nucleotide variants, indels, copy number alterations, structural variants, gene fusions, epigenetic changes and transcriptomic dysregulation. Advances in next-generation sequencing (NGS), including targeted panels, whole-exome and whole-genome sequencing, RNA sequencing, long-read technologies and single-cell approaches, have expanded genomic profiling and characterization of tumor heterogeneity. Integration with multi-omics and artificial intelligence supports molecular diagnosis, biomarker discovery, personalized therapy, inherited cancer-risk assessment, and minimal residual disease monitoring and treatment-resistance prediction. Thus, data shows the evolution and clinical applications of sequencing in oncology, highlighting its role in precision medicine and challenges involving analytical validity, variant interpretation, cost, data governance and clinical validation.

 

Keywords

Next-generation sequencing (NGS), cancer, genomics, whole-exome sequencing, precision oncology

 

Citation

Alshelali et al. Bioinformation 22(10): 6666-6670 (2026)

 

Edited by

Peter Natesan Pushparaj

 

ISSN

0973-2063

 

Publisher

Biomedical Informatics

 

License

This is an Open Access article which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. This is distributed under the terms of the Creative Commons Attribution License.